The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series

McMillan, Annabel; O’Neill, Aideen T; Townsend, William; Lambert, Jonathan; Virchis, Andres; Shah, Rakhee; Menezes, Leon; Humphries, Paul; Both, K Von; Grandage, Victoria; Carpenter, Ben; Hough, Rachael; Ardeshna, Kirit M.; Daw, Stephen

doi:10.1111/bjh.17274

Cited by 9 publications

(24 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35,46,47 This drug combination has never been explored in prospective pediatric clinical trials, and only three retrospective series of children and young adults with R/R HL have been reported, namely, our cohort, an American multicentric cohort of 29 patients, and an English monocentric cohort of 29 patients. [37][38][39] In…”

Section: Discussionmentioning

confidence: 99%

Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

Vinti

Pagliara

Buffardi

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25 years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8 mg/kg on day 1 and bendamustine 90-120 mg/m 2 on days 2 and 3.At the end of treatment, the overall response rate was 81%. The 3-year overall and progression-free survivals are 78.1% and 67%, respectively.

show abstract

Section: Discussionmentioning

confidence: 99%

Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

Vinti

Pagliara

Buffardi

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…27 Most recently, McMillan et al published their single center experience with BVB in pediatric and young adult patients, in which the median age of patients treated was 21 years old and CMR and OR rates were 79% and 83%, respectively. 17 Our study represents the first multicenter effort evaluating the safety and efficacy of BVB in a true pediatric cohort of patients (median age at time of BVB was 16 years old). While we are unable to make direct comparisons of our results against previously published treatments for children, these initial results compare favorably with existing salvage regimens.…”

Section: Discussionmentioning

confidence: 99%

“… 28 Most recently, McMillan et al published their single-center experience with BVB in pediatric and young adult patients in which the median age of patients treated was 21 years and CMR and objective response rates were 79% and 83%, respectively. 18 …”

Section: Discussionmentioning

confidence: 99%

“…15,16 However, there is limited data on the use of BVB in the pediatric population. 17 We conducted a multi-institution retrospective analysis of pediatric patients with R/R HL that received salvage treatment with BVB to obtain a better understanding of its tolerability and efficacy in this population.…”

Section: Introductionmentioning

confidence: 99%

“… 15 - 17 However, data on the use of BVB in the pediatric population are limited. 18 To obtain a better understanding of its tolerability and efficacy in this population, we conducted a multicenter retrospective analysis of pediatric patients with R/R HL who received salvage treatment with BVB.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma

Forlenza¹,

Gulati²,

Mauguen

et al. 2021

Blood Advances

View full text Add to dashboard Cite

In patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), achieving a complete metabolic response (CMR) following salvage therapy is associated with superior outcomes, and optimal treatments need to be identified. The combination of brentuximab vedotin and bendamustine (BVB), while highly active in adult patients, has not been extensively evaluated in pediatric patients with R/R HL. We performed a multi-institution retrospective review of pediatric patients <21 years of age with R/R HL treated with BVB from January 2016 to July 2019. Response was assessed by local radiologists according to Lugano classification criteria. Twenty-nine patients (17 relapsed, 12 refractory) with a median age of 15 years (range 10-20) were treated with BVB and received a median of three cycles of therapy (range 2-7). Patients received an infusion of 1.8mg/kg of brentuximab vedotin on day 1 with bendamustine 90mg/m2 on Days 1 and 2 of 3-week cycles. Nineteen patients (66%) achieved a CMR (CI: 46 to 82%). An objective response was observed in 23 patients (ORR 79%) (CI: 60 to 92%). The most common grade 3/4 toxicities were hematologic and 3 patients (10%) experienced grade 3 infusion reactions. Seventeen of 18 patients underwent successful mobilization and collection of stem cells. Sixteen patients (13 autologous, 3 allogeneic) received a consolidative transplant following BVB. The 3-year post-BVB event-free and overall survival was 65% (95%CI: 46 to 85%) and 89% (95%CI: 74 to 100), respectively. For pediatric patients with R/R HL, BVB was well tolerated and compares favorably with currently accepted salvage regimens.

show abstract

Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real‐life study

Massano

Carraro

Mussolin

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background: Brentuximab vedotin (BV) is an antibody drug-conjugated anti-CD30 approved for the treatment of adult classical Hodgkin's lymphoma (HL), whereas it is considered as off-label indication in paediatrics. The aim of the study was to evaluate the safety and efficacy of BV to treat patients aged less than 18 years with refractory/relapsed HL. Materials and methods:In this multicentre, retrospective study, 68 paediatric patients who received at least one dose of BV between November 2011 and August 2020 were enrolled. A median of nine doses of BV were administered as monotherapy (n = 31) or combined with other therapies (n = 37). BV was administrated alone as consolidation therapy after stem cell transplantation (SCT) in 12 patients, before SCT in 18 patients, whereas in 15 patients it was used before and after SCT as consolidation therapy. Median follow-up was 2.8 years (range: 0.6-8.9 years). Results:The best response was observed in the 86% of patients; the overall response rate was 66%. The 3-year progression-free survival was 58%, whereas the overall survival was 75%. No statistically significant differences between patients treated with BV monotherapy or combination were highlighted. In multivariate analysis, patients with non-nodular sclerosis HL and not transplanted had an increased risk of failure.Overall, 46% of patients had grade 3-4 adverse events that led to BV discontinuation in five of them. Conclusion:In conclusion, our study confirms that BV was a safe and effective drug, able to induce complete remission, either as monotherapy or in association with standard therapy.

show abstract

The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series

Cited by 9 publications

References 12 publications

Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma

Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a real‐life study

Contact Info

Product

Resources

About